Moderna Inc.

Moderna reported third-quarter revenue up 29% to $1.3 billion and net income of $162 million, far above the expected $885 million in revenue and an anticipated loss. The company raised its revenue forecast for the fiscal year to a gain of 15–25% and updated its year‑end cash expectation to $8.1–8.3 billion. The strong results pushed the stock sharply higher in premarket trading. » More on deraktionaer.de

Moderna shares have risen more than 650% year-to-date, significantly outperforming names like Micron and Nvidia. Drivers include mRNA technology, successful COVID-19 revenues and a diversified pipeline with respiratory vaccines, oncology programs and treatments for rare diseases. Attention is focused on Intismeran autolog and a phase‑3 combination with Keytruda in melanoma; on November 6 Moderna will release quarterly results and has confirmed revenue growth of up to 10% for the year. Investors are expecting further details on the flu vaccine and the oncology opportunities. » More on deraktionaer.de

An investment of $10,000 in Moderna on October 29, 2023 (closing price $71.91) would have grown to $29,782.37 by October 28, 2026 at a share price of $214.17. That corresponds to an increase of the original investment by 197.82%. Moderna was most recently valued at $85.63 billion; stock splits and dividends were not taken into account in the calculation. » More on finanzen.net

AstraZeneca announces plans to push into the cancer-vaccine business, driven by the success of personalized mRNA therapies from Moderna and Merck. CEO Pascal Soriot points to years of mRNA research, while oncology chief Dave Fredrickson concedes that competitors are currently further ahead. AstraZeneca is focusing on areas with high quality, pioneering roles and scale effects; the infectious-disease division will concentrate on non-personalized vaccines. The stock has recovered after consolidation, with the 200-day moving average at just under 13,500 pence an important technical hurdle; dividend yield around 2.0%, quarterly report on October 30. » More on deraktionaer.de

Moderna shares drop about eight percent, extending a correction after preliminary Intismeran data leaked. William Blair removed its buy rating and downgraded to "Market Perform", saying the success of the personalized melanoma vaccine still needs to be demonstrated in other tumor types. Analysts see potential for a new treatment standard but warn of substantial clinical and biological risks in expanding to kidney, bladder and lung cancer. » More on deraktionaer.de